Allena Pharmaceuticals Inc.

0.1190-0.0067-5.33%Vol 1.94M1Y Perf -90.76%
Jun 28th, 2022 16:00 DELAYED
BID0.1190 ASK0.1229
Open0.1300 Previous Close0.1257
Pre-Market- After-Market0.24
 - -  0.12 101.68%
Target Price
0.50 
Analyst Rating
Hold 3.00
Potential %
320.17 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
3.67 
Earnings Rating
Strong Buy
Market Cap10.68M 
Earnings Date
9th Aug 2022
Alpha-0.07 Standard Deviation0.25
Beta1.99 

Today's Price Range

0.11550.1300

52W Range

0.06831.45

5 Year PE Ratio Range

-5.40-1.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
7.80%
1 Month
2.61%
3 Months
-44.26%
6 Months
-80.00%
1 Year
-90.76%
3 Years
-96.91%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALNA0.1190-0.0067-5.33
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.20-0.1335.00
Q03 2021-0.18-0.175.56
Q02 2021-0.20-0.24-20.00
Q01 2021-0.21-0.210.00
Q04 2020-0.18-0.24-33.33
Q03 2020-0.21-0.22-4.76
Q02 2020-0.29-0.2610.34
Q01 2020-0.43-0.3127.91
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.0650.00Positive
9/2022 QR-0.0528.57Positive
12/2022 FY-0.3213.51Positive
12/2023 FY-0.2016.67Positive
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.06
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume1.94M
Shares Outstanding89.77K
Shares Float106.61M
Trades Count1.71K
Dollar Volume235.98K
Avg. Volume7.16M
Avg. Weekly Volume3.61M
Avg. Monthly Volume7.59M
Avg. Quarterly Volume10.29M

Allena Pharmaceuticals Inc. (NASDAQ: ALNA) stock closed at 0.1257 per share at the end of the most recent trading day (a 1.37% change compared to the prior day closing price) with a volume of 1.93M shares and market capitalization of 10.68M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 22 people. Allena Pharmaceuticals Inc. CEO is Louis Brenner.

The one-year performance of Allena Pharmaceuticals Inc. stock is -90.76%, while year-to-date (YTD) performance is -78.78%. ALNA stock has a five-year performance of %. Its 52-week range is between 0.0683 and 1.45, which gives ALNA stock a 52-week price range ratio of 3.67%

Allena Pharmaceuticals Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 1.15, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -162.93%, a ROC of -191.76% and a ROE of -288.91%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allena Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.06 for the next earnings report. Allena Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Allena Pharmaceuticals Inc. is Hold (3), with a target price of $0.5, which is +320.17% compared to the current price. The earnings rating for Allena Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allena Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allena Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 26.52, ATR14 : 0.02, CCI20 : 13.73, Chaikin Money Flow : -0.10, MACD : 0.00, Money Flow Index : 49.91, ROC : 6.08, RSI : 48.44, STOCH (14,3) : 31.93, STOCH RSI : 0.61, UO : 39.18, Williams %R : -68.07), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allena Pharmaceuticals Inc. in the last 12-months were: Louis Brenner (Option Excercise at a value of $0), Louis Brenner (Sold 40 328 shares of value $32 666 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
3.00
Hold
3.00
Hold
3.00

Allena Pharmaceuticals Inc.

Allena Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. The company's product candidate, reloxaliase, is a first-in-class, oral enzyme therapeutic for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, CKD and other serious kidney diseases.

CEO: Louis Brenner

Telephone: +1 617 467-4577

Address: One Newton Executive Park, Newton 02462, MA, US

Number of employees: 22

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

77%23%

Bearish Bullish

60%40%

Bearish Bullish

66%34%

TipRanks News for ALNA

Fri, 01 Apr 2022 16:31 GMT Allena Pharmaceuticals (ALNA) Receives a Hold from H.C. Wainwright

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 16:35 GMT Allena Pharmaceuticals (ALNA) Receives a Buy from B.Riley Financial

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 11:25 GMT Analysts Top Healthcare Picks: Allena Pharmaceuticals (ALNA), Unity Biotechnology (UBX)

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 11:15 GMT Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Allena Pharmaceuticals (ALNA) and Gritstone Oncology (GRTS)

- TipRanks. All rights reserved.

News

Stocktwits